Amgen's skin cancer drug hits main goal in late-stage trial

03/20/2013 | Reuters

Sixteen percent of patients who took Amgen's experimental advanced melanoma drug talimogene laherparepvec experienced at least partial tumor shrinkage for six months, compared with 2% of patients who received subcutaneous granulocyte-macrophage colony-stimulating factor, preliminary data from a late-stage trial showed. A detailed look at the study is set for release at a medical meeting this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations